SI2533050T1 - MoĹľnosti zdravljenja Fabrijeve bolezni - Google Patents

MoĹľnosti zdravljenja Fabrijeve bolezni

Info

Publication number
SI2533050T1
SI2533050T1 SI200731457T SI200731457T SI2533050T1 SI 2533050 T1 SI2533050 T1 SI 2533050T1 SI 200731457 T SI200731457 T SI 200731457T SI 200731457 T SI200731457 T SI 200731457T SI 2533050 T1 SI2533050 T1 SI 2533050T1
Authority
SI
Slovenia
Prior art keywords
treatment options
fabry disease
fabry
disease
options
Prior art date
Application number
SI200731457T
Other languages
English (en)
Inventor
David Lockhart
Jeff Castelli
Original Assignee
Amicus Therapeutics, Inc.
National Institutes Of Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38723987&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2533050(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics, Inc., National Institutes Of Health filed Critical Amicus Therapeutics, Inc.
Publication of SI2533050T1 publication Critical patent/SI2533050T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G01N2333/94—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Ecology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200731457T 2006-05-16 2007-05-16 MoĹľnosti zdravljenja Fabrijeve bolezni SI2533050T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80108906P 2006-05-16 2006-05-16
US85363106P 2006-10-23 2006-10-23
EP12168451.8A EP2533050B3 (en) 2006-05-16 2007-05-16 Treatment Options For Fabry Disease

Publications (1)

Publication Number Publication Date
SI2533050T1 true SI2533050T1 (sl) 2014-07-31

Family

ID=38723987

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200731457T SI2533050T1 (sl) 2006-05-16 2007-05-16 MoĹľnosti zdravljenja Fabrijeve bolezni
SI200731776A SI2787345T1 (sl) 2006-05-16 2007-05-16 Možnosti zdravljenja Fabrijeve bolezni

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200731776A SI2787345T1 (sl) 2006-05-16 2007-05-16 Možnosti zdravljenja Fabrijeve bolezni

Country Status (18)

Country Link
US (9) US7851143B2 (sl)
EP (5) EP2787345B8 (sl)
JP (6) JP2009537149A (sl)
AU (1) AU2007253900A1 (sl)
CA (1) CA2652553C (sl)
CY (3) CY1115180T1 (sl)
DK (2) DK2787345T3 (sl)
ES (3) ES2464527T7 (sl)
HK (3) HK1129458A1 (sl)
HU (2) HUE027569T2 (sl)
LT (1) LTC2787345I2 (sl)
LU (1) LU93312I2 (sl)
MX (2) MX351004B (sl)
NL (1) NL300843I2 (sl)
PL (2) PL2787345T3 (sl)
PT (1) PT2533050E (sl)
SI (2) SI2533050T1 (sl)
WO (1) WO2007137072A2 (sl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2533050T1 (sl) 2006-05-16 2014-07-31 Amicus Therapeutics, Inc. MoĹľnosti zdravljenja Fabrijeve bolezni
US9056101B2 (en) * 2007-04-26 2015-06-16 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
PT2252313E (pt) * 2008-02-12 2015-08-26 Amicus Therapeutics Inc Método para previsão da resposta ao tratamento farmacológico de doenças com chaperonas
CA2718059A1 (en) * 2008-03-12 2009-09-17 Amicus Therapeutics, Inc. Assays for diagnosing and evaluating treatment options for pompe disease
US9066939B2 (en) * 2009-11-17 2015-06-30 Baylor Research Institute Urinary triaosylceramide (GB3) as a marker of cardiac disease
CA2791994A1 (en) * 2010-03-05 2011-09-09 Baylor Research Institute Involvement of androgen/androgen receptor pathway in fabry disease
CN103974619B (zh) * 2011-03-11 2017-02-15 阿米库斯治疗学公司 治疗法布里病的给药方案
TR201906779T4 (tr) 2011-05-12 2019-05-21 Proteostasis Therapeutics Inc Proteostaz regülatörleri.
US20150258081A1 (en) * 2011-12-22 2015-09-17 Centogene Ip Gmbh Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
EP2806875B1 (en) 2012-01-25 2017-07-19 Proteostasis Therapeutics, Inc. Proteasome activity modulating compounds
WO2014127038A1 (en) * 2013-02-12 2014-08-21 Baylor Research Institute Methods and compositions related to calcium homeostasis and fabry disease
JP6546923B2 (ja) * 2013-12-23 2019-07-17 ビーシーエヌ ペプタイズ エセ．ア．Ｂｃｎ Ｐｅｐｔｉｄｅｓ Ｓ．Ａ． リソソーム蓄積障害または糖原病の処置における使用のためのエキソサイトーシス活性化化合物としてのビカルタミド類似体または（ｓ）−ビカルタミド
US9675627B2 (en) * 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses
US9957494B2 (en) 2014-07-25 2018-05-01 Shire Human Genetic Therapies, Inc. Crystal structure of human four-phosphate adaptor protein 2 glycolipid transfer protein like domain
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
US20190183869A1 (en) * 2016-07-19 2019-06-20 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naïve and ert-experienced patients
US11335461B1 (en) 2017-03-06 2022-05-17 Cerner Innovation, Inc. Predicting glycogen storage diseases (Pompe disease) and decision support
EP4062915A1 (en) * 2017-05-30 2022-09-28 Amicus Therapeutics, Inc. Migalastat bound to alpha galactosidase a
MX2019014410A (es) 2017-05-30 2020-02-10 Amicus Therapeutics Inc Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
US11923048B1 (en) 2017-10-03 2024-03-05 Cerner Innovation, Inc. Determining mucopolysaccharidoses and decision support tool
KR20200128676A (ko) 2018-02-06 2020-11-16 아미쿠스 세라퓨틱스, 인코포레이티드 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도
HRP20240025T1 (hr) * 2018-02-06 2024-03-29 Amicus Therapeutics, Inc. Liječenje bolesnika s klasičnom fabrijevom bolešću migalastatom
WO2020006269A1 (en) 2018-06-27 2020-01-02 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
AU2019295765A1 (en) 2018-06-27 2021-01-21 Yumanity, Inc. Proteasome activity enhancing compounds
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
AU2020327019A1 (en) 2019-08-07 2022-03-03 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene
US11191827B1 (en) * 2020-12-09 2021-12-07 Tevogen Bio Inc. COVID-19 peptide specific T-cells and methods of treating and preventing COVID-19
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463109A4 (en) * 1989-03-24 1992-11-19 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
CA2086413A1 (en) 1990-06-29 1991-12-30 Yohji Ezure Piperidine derivatives
US6270954B1 (en) 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
CA2250780A1 (en) 1996-04-10 1997-10-16 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US7842470B2 (en) 2001-10-09 2010-11-30 Oregon Health & Science University Method for pharmacoperones correction of GnRHR mutant protein misfolding
US20040180419A1 (en) 2003-01-31 2004-09-16 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiency disorders
US7446098B2 (en) * 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
CA2526173A1 (en) * 2003-05-22 2004-12-02 The Hospital For Sick Children Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity
FR2861991B1 (fr) 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
AU2004289327A1 (en) 2003-11-12 2005-05-26 Amicus Therapeutics Inc. Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat Gaucher disease
US9181184B2 (en) 2005-05-17 2015-11-10 Amicus Therapeutics, Inc. Method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
KR20080033242A (ko) 2005-06-08 2008-04-16 아미쿠스 세라퓨틱스, 인코포레이티드 리소좀 효소를 코딩하는 유전자의 돌연변이와 관련있는ｃｎｓ 질환의 치료 방법
ES2537089T3 (es) 2005-06-08 2015-06-02 Amicus Therapeutics, Inc. Purificación de imino- y amino-azúcares
JP2009502954A (ja) 2005-07-27 2009-01-29 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド タンパク質のミスフォールディングを修正する小分子及びその使用
WO2007089591A2 (en) 2006-01-27 2007-08-09 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for high throughput screening of pharmacological chaperones
SI2533050T1 (sl) * 2006-05-16 2014-07-31 Amicus Therapeutics, Inc. MoĹľnosti zdravljenja Fabrijeve bolezni
ATE500226T1 (de) 2006-09-22 2011-03-15 Krka Tovarna Zdravil D D Novo Mesto Aripiprazolhemifumarat und verfahren zu dessen herstellung
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc PROCESS FOR THE TREATMENT OF FABRY DISEASE USING PHARMACOLOGICAL CHAPERONS
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
US9056101B2 (en) 2007-04-26 2015-06-16 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
PT2252313E (pt) 2008-02-12 2015-08-26 Amicus Therapeutics Inc Método para previsão da resposta ao tratamento farmacológico de doenças com chaperonas
US8321148B2 (en) 2008-10-24 2012-11-27 Amicus Therapeutics, Inc. Multiple compartment dosing model
AU2010254092B2 (en) 2009-05-26 2015-11-12 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
US9206457B2 (en) 2009-05-26 2015-12-08 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
US9066939B2 (en) 2009-11-17 2015-06-30 Baylor Research Institute Urinary triaosylceramide (GB3) as a marker of cardiac disease
CN103974619B (zh) 2011-03-11 2017-02-15 阿米库斯治疗学公司 治疗法布里病的给药方案
US9694056B2 (en) 2012-07-17 2017-07-04 Amicus Therapeutics, Inc. α-galactosidase A and 1-deoxygalactonojirimycin co-formulation
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
JP7098529B2 (ja) 2016-03-22 2022-07-11 アミカス セラピューティックス インコーポレイテッド Ｇｌａ遺伝子にｇ９３３１ａ変異を有する患者においてファブリー病を処置する方法
US20190183869A1 (en) 2016-07-19 2019-06-20 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naïve and ert-experienced patients
JP2020503900A (ja) 2017-01-10 2020-02-06 アミカス セラピューティックス インコーポレイテッド ファブリー病の処置のための組換えアルファ−ガラクトシダーゼａ
MX2019014410A (es) 2017-05-30 2020-02-10 Amicus Therapeutics Inc Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
WO2019017938A1 (en) 2017-07-19 2019-01-24 Amicus Therapeutics, Inc. TREATMENT OF FABRY'S DISEASE IN PATIENTS WITHOUT SUBSTITUTED ENZYMATIC THERAPY (TES) AND PATIENTS SUBJECT TO TES
PL3675853T3 (pl) 2017-08-28 2022-12-27 Amicus Therapeutics, Inc. Sposoby poprawy i/lub stabilizacji czynności serca u pacjentów z chorobą fabry'ego
HRP20240025T1 (hr) 2018-02-06 2024-03-29 Amicus Therapeutics, Inc. Liječenje bolesnika s klasičnom fabrijevom bolešću migalastatom
KR20200128676A (ko) 2018-02-06 2020-11-16 아미쿠스 세라퓨틱스, 인코포레이티드 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도
KR20240017128A (ko) 2018-08-20 2024-02-06 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
KR20220019796A (ko) 2019-06-11 2022-02-17 아미쿠스 세라퓨틱스, 인코포레이티드 신장 손상을 갖는 환자에서 파브리 질병을 치료하는 방법
AU2020327019A1 (en) 2019-08-07 2022-03-03 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene

Also Published As

Publication number Publication date
JP2016006088A (ja) 2016-01-14
US20180250279A1 (en) 2018-09-06
EP2787345A1 (en) 2014-10-08
ES2573498T3 (es) 2016-06-08
PL2533050T6 (pl) 2016-05-31
US11241422B2 (en) 2022-02-08
MX2008014679A (es) 2009-04-14
HK1129458A1 (en) 2009-11-27
WO2007137072A2 (en) 2007-11-29
EP2024745A2 (en) 2009-02-18
JP6026268B2 (ja) 2016-11-16
US20180325881A1 (en) 2018-11-15
JP2023027053A (ja) 2023-03-01
CY1117656T1 (el) 2017-05-17
US20150238474A1 (en) 2015-08-27
ES2464527T9 (es) 2015-07-24
HUS1600048I1 (hu) 2017-01-30
US20120220632A1 (en) 2012-08-30
HK1218955A1 (zh) 2017-03-17
CY2016040I1 (el) 2017-06-28
US9480682B2 (en) 2016-11-01
US20080056994A1 (en) 2008-03-06
HK1178975A1 (en) 2013-09-19
PT2533050E (pt) 2014-05-26
JP6800176B2 (ja) 2020-12-16
HUE027569T2 (en) 2016-10-28
DK2533050T3 (da) 2014-06-02
LTC2787345I2 (lt) 2017-10-10
WO2007137072A3 (en) 2008-10-16
JP2018138564A (ja) 2018-09-06
EP2787345B8 (en) 2016-04-13
LTPA2016033I1 (lt) 2016-12-12
LU93312I2 (fr) 2017-01-26
CA2652553A1 (en) 2007-11-29
JP2020196717A (ja) 2020-12-10
EP2533050B3 (en) 2015-06-24
US20170042868A1 (en) 2017-02-16
US7851143B2 (en) 2010-12-14
CY1115180T1 (el) 2016-12-14
PL2787345T3 (pl) 2016-08-31
EP2024745A4 (en) 2010-03-17
MX351004B (es) 2017-09-26
DK2533050T6 (da) 2015-09-21
SI2787345T1 (sl) 2016-08-31
US20190388409A1 (en) 2019-12-26
ES2464527T7 (es) 2015-09-14
EP2955520A1 (en) 2015-12-16
EP2955520B1 (en) 2018-10-31
EP2787345B1 (en) 2016-02-24
US20110104727A1 (en) 2011-05-05
JP2013100307A (ja) 2013-05-23
AU2007253900A1 (en) 2007-11-29
PL2533050T3 (pl) 2014-08-29
US10383864B2 (en) 2019-08-20
JP7175297B2 (ja) 2022-11-18
EP2533050B1 (en) 2014-03-12
EP2024745B1 (en) 2015-07-08
JP2009537149A (ja) 2009-10-29
US9000011B2 (en) 2015-04-07
US10406143B2 (en) 2019-09-10
CY2016040I2 (el) 2017-06-28
NL300843I2 (sl) 2016-12-21
US9987263B2 (en) 2018-06-05
CA2652553C (en) 2020-08-18
DK2787345T3 (en) 2016-05-30
ES2464527T3 (es) 2014-06-03
ES2709445T3 (es) 2019-04-16
EP2533050A1 (en) 2012-12-12
EP3457135A1 (en) 2019-03-20
US20220160690A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
HUS1600048I1 (hu) Készítmény Fabry-kór kezelésére
GB0610680D0 (en) Therapeutic compounds
IL193678A0 (en) Therapeutic compounds
GB0624874D0 (en) Treatment
GB0603041D0 (en) Therapeutic compounds
HK1203925A1 (en) Therapeutic compounds
GB0600692D0 (en) Well treatment
GB0606663D0 (en) Therapeutic compounds
GB0615809D0 (en) Therapeutic compounds
EP1889618A4 (en) COMBINED MEDICINE FOR THE TREATMENT OF DIABETES
GB0612971D0 (en) Therapeutic compounds
GB0625349D0 (en) Therapeutic compounds
GB0607952D0 (en) Novel treatment
EP2079704A4 (en) THERAPEUTIC COMPOUNDS
GB0625345D0 (en) Therapeutic compounds
GB0701456D0 (en) Treatment for respiratory disease
GB0605573D0 (en) Therapeutic Compounds
GB0603455D0 (en) Therapeutic compounds
GB0604460D0 (en) Treatment
GB0608269D0 (en) Therapeutic compounds
GB2439923B (en) Therapeutic compounds
GB0604130D0 (en) Treatment for skin disease
GB0610431D0 (en) Treatment
GB0605781D0 (en) Treatment
GB0600817D0 (en) Medical treatment